Emergency Use Authorizations During the COVID-19 Pandemic —Lessons From Hydroxychloroquine for Upcoming Vaccine Approval
This Viewpoint uses the FDA ’s Emergency Use Authorization (EUA) of hydroxychloroquine for COVID-19 treatment to emphasize the costs of premature regulatory authorizations to public health and trust, and proposes the use of advisory committees, requirements for postmarketing surveillance, and adherence to standards of transp arency for any future EUAs.
Source: JAMA - Category: General Medicine Source Type: research
More News: COVID-19 | Emergency Medicine | General Medicine | Hydroxychloroquine | International Medicine & Public Health | Lessons | Pandemics | Vaccines